55
Participants
Start Date
April 5, 2017
Primary Completion Date
March 20, 2018
Study Completion Date
April 20, 2018
Plinabulin
a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
Pegfilgrastim
PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Kirovograd Regional Oncological Center, Kropyvnytskyi
Cancer Center of Middle Georgia, Dublin
Mid Florida Hematology & Oncology Center, Orange City
"Municipal Institution Sumy Regional Clinical Oncology Dispensary", Sumy
Municipal Institution Dnipropetrovsk City Multi-functional Hospital, Dnipro
"Regional Municipal Institution Kryvyy Rig Oncology Dispensary", Krivói Rog
Hematology/Oncology of the North Shore, Skokie
Kherson regional oncological dispensary Communal Institution of Kherson Regional council, Kherson
Prykarpatian Clinical Oncological Center, Ivano-Frankivsk
Lviv State Oncological Regional Treatment and Preventive Center, Lviv
Zakarpattia Regional Clinical Oncology Center, Uzhhorod
Emad Ibrahim, MD, Inc., Redlands
Harbin Medical University Cancer Hospital, Harbin
Jiangsu Cancer Hospital, Nanjing
"SBI of Healthcare Oncology Dispensary #2 Ministry of Healthcare of Krasnodar Region", Sochi
Volgograd Regional Clinical Oncology Dispensary, Volgograd
Medical University 'REAVIZ', Samara
Henan Cancer Hospital, Zhengzhou
Kyiv City Clinical Oncology Center, Kyiv
Lead Sponsor
BeyondSpring Pharmaceuticals Inc.
INDUSTRY